Heart failure and chronic kidney disease frequently co-exist and convey bad outcome.

Treatments of the cardiorenal syndrome target fluid overload and venous congestion.

New therapies are serelaxin and angiotensin receptor blockade with neutral endopeptidase inhibition.

Markers of glomerular or tubular renal injury are helpful in cardiorenal syndrome.

Emerging blood or urine markers are currently tested.